Can Altimmune get its GLP-1 Drug to Market Before Cash Rush Out?
Altimmune Inc. NASDAQ: ALT is a clinical-stage biotechnology company specializing in treating liver disease and obesity. Their lead drug, Pemvidutide, has garnered much attention as a GLP-1/glucagon dual agonist similar to the weight-loss treatments Mounjaro and Zepbound by Eli Lilly and Co. NYSE:…#altimmuneinc #alt #pemvidutide #glp1 #mounjaro #elilillyandco #lly #ozempicandwegovy #novonordiskasnyse #nvo
Source: Reuters: Health - Category: Consumer Health News Source Type: news
More News: Biotechnology | Eating Disorders & Weight Management | Health | Liver | Liver Disease | Obesity | Urology & Nephrology | Weight Loss